A New Treatment Strategy for Asthma: SMART (Symbicort(R) Maintenance And Reliever Therapy).
10.5124/jkma.2007.50.3.279
- Author:
Hae Sim PARK
1
;
Young Min YE
Author Information
1. Department of Internal Medicine, Ajou University College of Medicine, Korea. hspark@madang.ajou.ac.kr, ye9007@hanmail.net
- Publication Type:Original Article
- Keywords:
Asthma;
ICS and LABA combination;
SMART
- MeSH:
Adrenal Cortex Hormones;
Asthma*;
Budesonide;
Cough;
Formoterol Fumarate;
Inflammation;
Lung;
Nebulizers and Vaporizers;
Respiratory Sounds;
Steroids;
Thorax
- From:Journal of the Korean Medical Association
2007;50(3):279-283
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Asthma is characterized by chronic inflammation of the airways with variable airflow limitation resulting in recurrent wheezing, chest tightness, and cough. Long term management is essential to prevent symptom and asthma exacerbation with using daily controller medications. Asthma control was much improved by combining inhaled corticosteroids with long-acting beta2 agonists. Recent several studies demonstrated the effectiveness of a new asthma management strategy, a single inhaler containing budesonide and formoterol for both maintenance therapy and symptom relief (called SMART) which was approved in GINA guideline, 2006. This SMART strategy could reduce the frequency of severe exacerbations and the need for rescue medicine with systemic steroids as well as improved lung function and asthma controls at relatively lower doses of corticosteroid with lesser costs for treatment.
